A news story from the health sector has turned out to be the happiest and biggest news of the day. As per many reports, the cure for cancer has been finally found.
Cancer is a deadly disease and has affected various people and families in the most adverse ways. Reportedly, in 2015, about 90.5 million people worldwide had cancer. In 2019, annual cancer cases grew to 23.6 million people and 10 million deaths worldwide, representing over the previous decade increases of 26% and 21%, respectively.
Reports of Hindustan Times also suggest that Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths, according to the World Health Organization (WHO). In 2020, the most common cancers are breast (2.26 million cases), lung (2.21 million cases), colon and rectum (1.93 million cases), and prostate cancers (1.41 million cases).
But now, a new ray of hope has spread positivity in the world which suggests that a cure for Cancer has been finally found. Recently a small clinical trial was held in the US which turned out to be 100% successful.
Yes, you read that right. It was a trial for a cure for cancer and it was one hundred percent successful. A drug named Dostarlimab was tested on 18 patients suffering from cancer. They were served the medication for almost six months, and as a result, each one of them got rid of their tumors.
As per the reports of the New York Times, the eighteen patients had undergone chemotherapy, radiation and, most likely, life-altering surgery that could result in the bowel, urinary and sexual dysfunction.
Also Read: Esha Gupta Raises The Temperature In Floral Saree! Takes The Internet By Storm
Something like this has happened for the first time in the history of Cancer. And the results of the clinical trial gave the patients many happy tears, said Dr Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center.
Dostarlimab drug will now be tested on a bigger scale than earlier. The medical experts are extremely astonished by the results of this trial and have high hopes for the second stage of trials.